The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

For decades, lab-made antibodies have been used to support patients fighting specific diseases. These treatments have become ...

Some people may remain ill after COVID infection because the virus still lurks in their bodies. The looming question now is: ...

Immune cell populations of people with post-vaccination syndrome had lower levels of effector CD4 T cells and higher levels ...

Yale researchers have examined post-vaccination syndrome (PVS), identifying persistent symptoms like fatigue and brain fog.

Tixagevimab-cilgavimab reduced risk for severe COVID-19 progression in patients with hematologic malignancies on anti-CD20 therapy during the early Omicron era.

A new study shows non-menopausal women between the ages of 40 and 54 had a significantly higher risk of developing long covid ...

Certain antiviral and mAb therapies were shown to lower mortality and hospitalization rates in those infected with SARS-CoV-2 Omicron variants.

Multiple vaccine shots are needed to boost vasculitis patients’ immunity against COVID, especially if they have been treated ...

Vermont has the second lowest state fatality rate in the US (145.3 per 100K; Hawaii 112.6/100K). Mississippi (461.9/100K) and ...